Parsortix system

January 30, 2017

ANGLE Announces Positive Interim Evaluation of Ovarian Cancer Clinical Studies

News

ANGLE has completed the planned interim analysis of two clinical studies, in Europe and the United States, evaluating its Parsortix system in women with ovarian cancer. The data has shown that the system can accurately ... Read more

August 24, 2016August 24, 2016

Analytic Tool Aiding Clinical Studies of Ganetespib for Advanced Ovarian Cancers

News

Parsortix, a system developed by Angle Plc. to harvest circulating tumor cells in the blood of cancer patients, has been used as part of the GANNET 53 project testing the ... Read more

July 20, 2016July 20, 2016

Angle’s European Ovarian Cancer Trial Enrolls First Patient

News

Angle PLC has recruited the first patient for its European ovarian cancer trial (ANG-001), which aims to enroll 200 women diagnosed with a pelvic mass via imaging studies who are scheduled to undergo ... Read more